
NVCR
NovoCure Limited
$13.32
-$0.34(-2.49%)
58
Overall
60
Value
72
Tech
42
Quality
Market Cap
$1.42B
Volume
1.16M
52W Range
$10.70 - $34.13
Target Price
$25.36
Company Overview
| Mkt Cap | $1.42B | Price | $13.32 |
| Volume | 1.16M | Change | -2.49% |
| P/E Ratio | -8.4 | Open | $13.58 |
| Revenue | $605.2M | Prev Close | $13.66 |
| Net Income | $-168.6M | 52W Range | $10.70 - $34.13 |
| Div Yield | N/A | Target | $25.36 |
| Overall | 58 | Value | 60 |
| Quality | 42 | Technical | 72 |
No chart data available
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVCR | $13.32 | -2.5% | 1.16M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |